Century TherapeuticsIPSC -2.60%46 Cash Ratio is 9.94 as of Mar. 2026, which is 5% below its 10-year median of 10.43. GuruFocus rates IPSC with a GF Score™ of 46/100 and a GF Value™ of $39.00 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,386 Biotechnology companies, Century Therapeutics ranks better than 80.01% on this metric.
Century Therapeutics has a Cash Ratio of 9.94. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Century Therapeutics's Cash Ratio or its related term are showing as below:
IPSC'
s Cash Ratio Range Over the Past 10 Years
Min: 1.46 Med: 10.43 Max: 27.23
Current: 9.94
During the past 7 years, Century Therapeutics's highest Cash Ratio was 27.23. The lowest was 1.46. And the median was 10.43.
IPSC's Cash Ratio is ranked better than 80.01% of 1386
companies
in the Biotechnology industry
Industry Median: 2.93
vs IPSC: 9.94
Century Therapeutics (NAS:IPSC) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Century Therapeutics Cash Ratio Related Terms
Century Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Century Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Century Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Century Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Century Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Century Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Century Therapeutics (IPSC) has a Cash Ratio of 9.94 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Century Therapeutics and its competitors. This is near median its historical median of 10.43. Over the past decade, Century Therapeutics' Cash Ratio has ranged from 1.46 to 27.23. According to the industry distribution chart, Century Therapeutics ranks #277 out of 1386 companies in the Biotechnology industry, placing it in the top 20%.
Is Century Therapeutics' Cash Ratio too high?
Century Therapeutics' current Cash Ratio of 9.94 is near median its 10-year median of 10.43. Over the past 10 years, this metric has ranged from a low of 1.46 to a high of 27.23. The Biotechnology industry median Cash Ratio is 2.93. Century Therapeutics' value of 9.94 is 239.2% above this industry median. Based on the distribution chart, Century Therapeutics ranks #277 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' Cash Ratio compare to PBYI and BNTC?
According to the Biotechnology industry distribution chart, Century Therapeutics ranks #277 out of 1386 companies for Cash Ratio. This places Century Therapeutics in the top 20% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Century Therapeutics' value of 9.94 is 239.2% above this benchmark. Historically, Century Therapeutics' own Cash Ratio has ranged from 1.46 to 27.23 over the past decade. While the company's 10-year median is 10.43 vs. the industry median of 2.93, Century Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Century Therapeutics's current Cash Ratio of 9.94 is 239.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Century Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Century Therapeutics's current Cash Ratio is 9.94, which is near median its own 10-year median of 10.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $39.00, compared to a current price of $2.26 — trading 94.2% below its estimated fair value. The current Cash Ratio is 9.94, which is near median its 10-year median of 10.43 and 239.2% above the Biotechnology industry median of 2.93. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current Cash Ratio is 9.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Century Therapeutics (IPSC) Overvalued in 2026?
Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued.
The current stock price of $2.26 is trading 94.2% below its estimated GF Value™ of $39.00.
GuruFocus considers Century Therapeutics to be Possible Value Trap.
Key valuation signals for IPSC:
Cash Ratio: 9.94 (near median its 10-year median of 10.43)
GF Value™: $39.00 vs. price of $2.26 (94.2% below fair value)
Industry Position: 239.2% above the Biotechnology median (#277 of 1386)
No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score
Get the complete analysis for IPSC
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPSC has been successfully added to your 
